
CLAIMS

1. A composition comprising a non-pegylated aptamer 5′ NH_2-fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUfUAfCfCfUmGf CmG-3T-3′ (SEQ ID NO: 1), wherein:
   (a) more than 85% of the aptamer in the composition is full length aptamer, and wherein the composition comprises:
   (b) less than 1.8% of G cleavage products,
   (c) 1% or less of deprotection failure products,
   (d) less than 0.1% of A cleavage products,
   (e) less than 1.1% of n-4, n-3 and n-2 deletion products, and
   (f) less than 3% of fluoro degradants and n-1 deletion products.

2. The composition of claim 1, wherein:
   (a) 88.3% - 91.8% of the aptamer in the composition is full length aptamer; and wherein the composition comprises:
   (b) 1.06% - 1.71% of G cleavage products,
   (c) 0.55% - 1.00% of deprotection failure products,
   (d) 0% - 0.08% of A cleavage products, and
   (e) 2.12% - 2.86% of fluoro degradants and n-1 deletion products.

3. A composition comprising a PEGylated aptamer having the structure:



or a salt thereof, wherein the aptamer comprises the sequence of SEQ ID NO: 1,

wherein:

   (a) more than 92% of the aptamer in the composition is full length aptamer; and

(b) less than 5% of the composition is relative retention time 2 (RRT2) (>full length product (FLP) – ≤1.2).

4. The composition of claim 3 wherein:
   (a) 93.0% - 94.0% of the aptamer in the composition is full length aptamer,
   (b) 3.00% - 4.74% of the composition is RRT 2 (>FLP – ≤1.20), and
   (c) 1.97% - 2.65% of the composition is RRT 1 (≥0.93 – <FLP).

5. The composition of claim 3, wherein the PEGylated aptamer comprises a 2-arm branched PEG ranging from approximately 39 kDa to approximately 47 kDa.

6. The composition of claim 3, wherein the PEGylated aptamer comprises a 2-arm branched PEG of approximately 40 kDa.

7. The composition of claim 3, wherein the PEGylated aptamer comprises a 2-arm branched PEG of approximately 43 kDa.

8. The composition of claim 3, wherein the salt is a sodium salt.

9. The composition of claim 8, wherein the composition is at least 5% more potent at inducing a complement cascade, as measured by ELISA, as compared to a control composition, wherein:
   (a) 90.6% of the aptamer in the control composition is full length product,
   (b) 1.3% of the control composition is RRT 1 (≥0.93 – <FLP), and
   (c) 8.15% of the control composition is RRT 2 (>FLP – ≤1.20).

10. The composition of claim 3, comprising one or more pharmaceutically acceptable excipients.

11. The composition of claim 3, wherein the composition is a sterile aqueous solution comprising 20 mg/mL of the aptamer and phosphate-buffered saline and having a pH in the range of 6.8-7.8.

12. The composition of claim 11, wherein the composition has a pH of 7.3.

13. The composition of claim 3, wherein the composition has an osmolality between 350 mOsM/kg to 500 mOsM/kg.

14. The composition of claim 3 for use as a medicament.

15. The composition of claim 14 for use in the treatment of geographic atrophy secondary to age-related macular degeneration.

16. The composition of claim 15, wherein a dose is between 1 mg/eye to 5 mg/eye.

17. The composition of claim 16, wherein the dose is about 2 mg/eye.

18. The composition of claim 15, wherein a dose of about 100 µL of the composition per eye is to be administered.

19. The composition of any one of claims 16 to 18, wherein the dose is to be administered once monthly.

20. The composition of any one of claims 16 to 18, wherein the dose is to be administered once every 28±7 days.